[1] Piano S, Dalbeni A, Vettore E, Benfaremo D, Mattioli M, Gambino CG, et al. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. Liver Int 2020;40(10):2394 − 406. http://dx.doi.org/10.1111/liv.14565CrossRef
[2] Cai QX, Huang DL, Yu H, Zhu ZB, Xia Z, Su YN, et al. COVID-19: abnormal liver function tests. J Hepatol 2020;73(3):566 − 74. http://dx.doi.org/10.1016/j.jhep.2020.04.006CrossRef
[3] Kambhampati S, Bauer KE, Bracci PM, Keenan BP, Behr SC, Gordan JD, et al. Nivolumab in patients with advanced hepatocellular carcinoma and child-pugh class B cirrhosis: safety and clinical outcomes in a retrospective case series. Cancer 2019;125(18):3234 − 41. http://dx.doi.org/10.1002/cncr.32206CrossRef
[4] Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu LH, et al. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology 2020;72(2):389 − 98. http://dx.doi.org/10.1002/hep.31301CrossRef
[5] Mo PZ, Xing YY, Xiao Y, Deng LP, Zhao Q, Wang HL, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis 2020ciaa270. http://dx.doi.org/10.1093/cid/ciaa270CrossRef
[6] Hundt MA, Deng YH, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal liver tests in COVID-19: a retrospective observational cohort study of 1,827 patients in a major U.S. hospital network. Hepatology 2020;72(4):1169 − 76. http://dx.doi.org/10.1002/hep.31487CrossRef
[7] de Avelar CR, Pereira EM, de Farias Costa PR, de Jesus RP, de Oliveira LPM. Effect of silymarin on biochemical indicators in patients with liver disease: systematic review with meta-analysis. World J Gastroenterol 2017;23(27):5004 − 17. http://dx.doi.org/10.3748/wjg.v23.i27.5004CrossRef
[8] Xie KL, Chen CH, Tsai SP, Lu PJ, Wu H, Zeng Y, et al. Loss of life expectancy by 10 years or more from elevated aspartate aminotransferase: finding aspartate aminotransferase a better mortality predictor for all-cause and liver-related than alanine aminotransferase. Am J Gastroenterol 2019;114(9):1478 − 87. http://dx.doi.org/10.14309/ajg.0000000000000332CrossRef
[9] Chughlay MF, Akakpo S, Odedra A, Csermak-Renner K, Djeriou E, Winnips C, et al. Liver enzyme elevations in Plasmodium falciparum volunteer infection studies: findings and recommendations. Am J Trop Med Hyg 2020;103(1):378 − 93. http://dx.doi.org/10.4269/ajtmh.19-0846CrossRef
[10] National Health Commission of the People’s Republic of China. Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7). 2020. http://en.nhc.gov.cn/2020-03/29/c_78469.htm. [2021-3-2]http://en.nhc.gov.cn/2020-03/29/c_78469.htm
[11] Wang YM, Zhang DY, Du GH, Du RH, Zhao JP, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395(10236):1569 − 78. http://dx.doi.org/10.1016/s0140-6736(20)31022-9CrossRef
[12] Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev 2020;47:100761. http://dx.doi.org/10.1016/j.blre.2020.100761CrossRef
[13] Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care 2020;24(1):360. http://dx.doi.org/10.1186/s13054-020-03077-0CrossRef
[14] Wu YY, Li HY, Guo XZ, Yoshida EM, Mendez-Sanchez N, Sandri GBL, et al. Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis. Hepatol Int 2020;14(5):621 − 37. http://dx.doi.org/10.1007/s12072-020-10074-6CrossRef
[15] Medetalibeyoglu A, Catma Y, Senkal N, Ormeci A, Cavus B, Kose M, et al. The effect of liver test abnormalities on the prognosis of COVID-19. Ann Hepatol 2020;19(6):614 − 21. http://dx.doi.org/10.1016/j.aohep.2020.08.068CrossRef
[16] Zhang GM, Zhang GM, Hu S, Peng YF, Gu B. Is testing of aspartate aminotransferase necessary along with every alanine aminotransferase for health check in elderly individuals? Clin Chim Acta 2020;507:224 − 7. http://dx.doi.org/10.1016/j.cca.2020.05.003CrossRef